OTCMKTS:LOGC

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

LogicBio Therapeutics logo
$12.95 -0.05 (-0.38%)
As of 10:33 AM Eastern

About LogicBio Therapeutics Stock (OTCMKTS:LOGC)

Advanced

Key Stats

Today's Range
$12.95
▼
$13.00
50-Day Range
$13.00
▼
$15.46
52-Week Range
$7.05
▼
$15.60
Volume
5,027 shs
Average Volume
136,169 shs
Market Capitalization
$592.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LogicBio Therapeutics, Inc. was a biotechnology company focused on developing genomic medicines for rare diseases, particularly conditions affecting children. Its research centered on approaches intended to address the underlying genetic causes of disease.

The company developed GeneRide, a genome-editing platform designed to integrate therapeutic genetic material into a patient’s DNA. Its lead program, LB-001, was investigated for methylmalonic acidemia, a rare inherited metabolic disorder. LogicBio also worked on sAAVy, a platform for discovering and developing adeno-associated virus vectors for gene delivery.

Alexion Pharmaceuticals, part of AstraZeneca, completed its acquisition of LogicBio in 2022. LogicBio’s programs and platforms therefore became part of Alexion’s rare-disease research activities.

AI Generated. May Contain Errors.

LogicBio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

LOGC MarketRank™: 
0.487137383685 of 5 stars

LogicBio Therapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for LogicBio Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LogicBio Therapeutics is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LogicBio Therapeutics is -13.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LogicBio Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    2.15% of the float of LogicBio Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 5.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently increased by 8.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    LogicBio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LogicBio Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    LogicBio Therapeutics has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for LogicBio Therapeutics this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    2 people have added LogicBio Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    42.47% of the stock of LogicBio Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LogicBio Therapeutics' insider trading history.
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LOGC Stock News Headlines

CFA: Bank of America Said THIS
On January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.tc pixel
ContextLogic to Acquire gChem for $850 Million
See More Headlines

LOGC Stock Analysis - Frequently Asked Questions

LogicBio Therapeutics' stock was trading at $7.58 at the beginning of 2026. Since then, LOGC shares have increased by 71.5% and is now trading at $13.00.

LogicBio Therapeutics, Inc. (OTCMKTS:LOGC) released its quarterly earnings results on Monday, November, 9th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.25. The business had revenue of $32.20 million for the quarter, compared to the consensus estimate of $32.20 million.

Shares of LOGC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Editas Medicine (EDIT), Precision BioSciences (DTIL), Gossamer Bio (GOSS), Alector (ALEC), Kaleido Biosciences (KLDO), HOOKIPA Pharma (HOOK) and Cabaletta Bio (CABA).

Company Calendar

Last Earnings
11/09/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
OTCMKTS:LOGC
CIK
1664106
Fax
N/A
Employees
62
Year Founded
2014

Profitability

EPS (Trailing Twelve Months)
($0.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29 million
Net Margins
N/A
Pretax Margin
-79.53%
Return on Equity
-2.86%
Return on Assets
-2.14%

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
1.43
Quick Ratio
0.94

Sales & Book Value

Annual Sales
$10.16 million
Price / Sales
58.28
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$15.80 per share
Price / Book
0.82

Miscellaneous

Outstanding Shares
45,731,000
Free Float
26,309,000
Market Cap
$592.22 million
Optionable
No Data
Beta
2.11

Social Links

7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

This page (OTCMKTS:LOGC) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners